期刊文献+

小剂量CF解救ALL患儿HD-MTX化疗的毒副作用观察 被引量:2

The Observation of Small Dose CF Deal With the Toxic and Side Effect Cause by HD-MTX Treating ALL Children
下载PDF
导出
摘要 目的探讨急性淋巴细胞性白血病(ALL)患儿应用大剂量甲氨喋呤(HD-MTX)化疗后小剂量四氢叶酸钙(CF)解救的可能性及护理体会。方法将17例确诊急性淋巴细胞性白血病中危型患儿的66例次HD-MTX-CF化疗随机分为观察组和对照组,减少观察组的36例次的HD-MTX化疗后CF的解救剂量至1.5%,对照组的30例次解救剂量仍为常规的3.5%。观察所有患儿的毒副反应,并监测血药浓度。结果对照组的30例化疗中有2例出现口腔黏膜溃烂,3例出现呕吐;观察组的36例化疗中,有2例出现口腔黏膜溃烂,5例出现呕吐,P>0.05,差异不具有统计学意义。结论在严格进行各项护理操作、同时检测MTX血药浓度的情况下,应用小剂量四氢叶酸钙解救急性淋巴细胞性白血病患儿比较安全。 Objective To discuss the possibility of small dose calcium folinate (CF) dealing with the bed effect caused by high dose methotrexate (HD-MTX) treating children with acute lymphoblastic leukemia (ALL) and the nursing care.Methods Selected 17 cases of the ALL patients were treated 66 using HD-MT. The treatments divided into two groups randomly, the observe group had 36 cases and the control group 30 cases. The observe group were given the dose of CF 1.5% after treating by HD-MTX, the control group were given the dose of CF 3.5% after treating by HD-MTX. collected the side effects and monitored the blood concentration.Results There were 5 emesis and 2 oral ulcer of the observe group and 3 emesis and 2 oral ulcer of the control group,P〉0.05, had difference statistically signiifcance.Conclusion It was safe to use small dose CF dealing with the side effect casing by HD-MTX under monitoring MTX blood concentration and nursing carefully.
作者 张香丽 薛靖
出处 《中国继续医学教育》 2015年第29期183-184,共2页 China Continuing Medical Education
关键词 四氢叶酸钙 甲氨喋呤 急性淋巴细胞性白血病 儿童 解救 Calcium folinate Methotrexate Acute lymphoblastic leukemia Children Deal with
  • 相关文献

参考文献9

二级参考文献21

  • 1湛洁谊,叶铁真,吴梓梁,陈福雄,邹亚伟,王波.大剂量甲氨蝶呤治疗急性淋巴细胞白血病[J].实用儿科临床杂志,2005,20(7):652-654. 被引量:15
  • 2李黎波,李金翰,徐峰.大剂量甲氨喋呤静滴后解救剂甲酰四氢叶酸钙的个体化用药[J].实用癌症杂志,1995,10(4):261-263. 被引量:6
  • 3彭健,姚敏元.大剂量氨甲喋呤治疗儿童急性淋巴细胞白血病的药代动力学[J].中国药房,1996,7(2):77-77. 被引量:13
  • 4顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 5Enans WF, Crom WR, Abromowich M, et al. Clinical pharmacodynamic of high-dose methotrexate in acute lymphoblastic leukemia [J]. NEngl Jmed,1986,314:471-4.
  • 6Aplene R, thompson J, Han P, et al. Methylenetetrahydrofolate reductasa polymorphisms and therapy response in pediatric acute lymphoblastic leukemia[ J]. Cancer Res ,2005,65 ( 6 ) :2482 - 7.
  • 7Krajinovic M, Moghrabi A. Pharamacogenetics of methtrexate [ J ]. Pharmacogenomics ,2004,5 ( 7 ) :89 - 34.
  • 8Evans WE, Relling MV, Boyett JM, et al. Dose pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of childrren with acute lymphoblastic leukemia:what can we learn from small studies[ J]. Leuk res, 1997,21: 435 -7.
  • 9Reiter A,Schrappe M,Ludwig WD,et al.Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients.Results and conclusions of the multicenter trial ALL-BFM 86[J].Blood,1994,84(9):3122-3133.
  • 10Evans WE,Relling MV,Boyett JM,et al.Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia:what can we learn from small studies[J]? Leuk Res,1997,21(5):435-437.

共引文献511

同被引文献14

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部